



XXIX CONGRESO NACIONAL  
**CACI2019**

*Pilar*



## QUIENES SOMOS

**MTG** es una empresa argentina con más de veinte años de trayectoria que representa en forma exclusiva compañías extranjeras fabricantes de dispositivos médicos e implantes de la más alta calidad y **reconocimiento científico a nivel mundial.**

## NUESTRO OBJETIVO

Satisfacer la creciente demanda del **mercado de la salud.**

Sebastian Zeme  
Gerente de Ventas  
[szeme@mtg-group.com.ar](mailto:szeme@mtg-group.com.ar)  
+541158889950



XXIX CONGRESO NACIONAL  
**CACI2019**

*Pilar*



**COBERTURA GEOGRAFICA**  
Oficinas en C.A.B.A, Rosario y Córdoba



Buenos Aires  
Catamarca  
Chaco  
Córdoba  
Corrientes  
Entre Ríos  
Formosa  
La Pampa  
La Rioja  
Mendoza  
Misiones  
Río Negro  
Salta  
San Juan  
San Luis  
Santa Fe  
Santiago del Estero  
Tierra del Fuego  
Tucumán



XXIX CONGRESO NACIONAL  
**CACI2019**

*Pilar*



# NOVEDADES DE FIREHAWK




XXIX CONGRESO NACIONAL  
**CACI2019**

*Pilar*

# TARGET AC TRIAL FIREHAWK

Stent coronario liberador  
de Rapamicina con  
polímero reabsorbible



 **MicroPort**

 **MTG GROUP**





XXIX CONGRESO NACIONAL  
**CACI2019**

*Pilar*



## Know your TARGET – Target AC 1 year result

# THE LANCET

a weekly peer-reviewed general medical journal.

*The Lancet* was founded in 1823, was ranked second (with an impact factor of **53.254**).



# THE LANCET

[www.thelancet.com](http://www.thelancet.com)

## Reprint

➔ Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial

Alexandra Lansky, William Wijns, Bo Xu, Henning Kelbæk, Niels van Royen, Ming Zheng, Marie-angèle Morel, Paul Knaapen, Ton Slagboom, Thomas W Johnson, Georgios Vlachojannis, Karin E Arkenbout, Lene Holmvang, Luc Janssens, Andrzej Ochala, Salvatore Brugaletta, Christoph K Naber, Richard Anderson, Harald Rittger, Sergio Berti, Emanuele Barbato, Gabor G Tóth, Luc Maillard, Christian Valina, Paweł Buszman, Holger Thiele, Volker Schächinger, Andreas Baumbach, for the TARGET All Comers Investigators

[https://doi.org/10.1016/S0140-6736\(18\)31649-0](https://doi.org/10.1016/S0140-6736(18)31649-0)




XXIX CONGRESO NACIONAL  
**CACI2019**

*Pilar*




## Know your TARGET – Target AC 2 year result



**JACC**  
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Impactor Factor **18.639**.






XXIX CONGRESO NACIONAL  
**CACI2019**

*Pilar*



## TARGET AC: Trial Design



- **Primary Endpoint:** TLF (ARC defined) = Cardiac Death, Target Vessel MI, ID-TLR @ 12mo
- **Secondary Endpoint (powered):** in-stent late loss @ 13mo; mean neo-intimal thickness @ 3mo
- **Secondary Endpoints:** TLF @ 30d, 6mo, 2 - 5 yr; Composite (all death, all MI, any revasc) at each
- **FU time point;** QCA parameters @ 13 mo; OCT parameters @ 3 mo
- **DAPT:** ASA and P2Y12 inhibitor > 6 months (per guidelines)





XXIX CONGRESO NACIONAL  
**CACI2019**

*Pilar*



# TARGET AC Management

<b>Executive Operations Committee</b>	<p>TARGET All Comers Trial</p> <p>Chair:</p> <ul style="list-style-type: none"> <li>William Wijns, MD (Galway, Ireland)</li> </ul> <p>CO-PI's:</p> <ul style="list-style-type: none"> <li>Andreas Baumbach, MD (Bristol, UK)</li> <li>Alexandra Lansky, MD (New Haven, US)</li> </ul> <p>Other Committee Members:</p> <ul style="list-style-type: none"> <li>XU Bo, MBBS (Beijing, China)</li> <li>Zheng Ming, MD (Shanghai, China)</li> <li>Laure Artus-Jacenko, D.E.S.S. (Paris, France)</li> </ul>
<b>Clinical Events Committee</b>	<p>CON plc, (Dublin, Ireland.)</p> <p>Chair: Michael Gibson, MD (Boston, US)</p>
<b>Data Safety Monitoring Board</b>	<p>Cardialysis, (Rotterdam, The Netherlands)</p> <p>Chair: Stefan James, MD (Uppsala, Sweden)</p>
<b>Angiographic Core Lab</b>	<p>Cardialysis, (Rotterdam, The Netherlands)</p> <p>CCRF, (Beijing, China)</p>
<b>OCT Core Lab</b>	<p>Cardialysis, (Rotterdam, The Netherlands)</p> <p>Dr Y. Onuma and team</p>
<b>Data Management</b>	<p>CON plc, (Dublin, Ireland.)</p>

21 sites 10 countries from EU




Austria | Belgium | Denmark | France | Germany  
Italy | The Netherlands | Poland | Spain | UK





# Target AC Trial: Study Subjects follow-up flow

## 2-year Follow-up Flow





XXIX CONGRESO NACIONAL  
**CACI2019**

*Pilar*



## Target AC Trial – 2 year results

### Clinical Outcomes at 2-year Follow-up (1)

	FIREHAWK, N=778	XIENCE, N=791	Difference (95% CI)	P value
Target lesion failure	8.7% (68)	8.6% (68)	0.1% (-2.6% to 2.9%)	0.92
Target vessel failure	9.9% (77)	9.6% (76)	0.3% (-2.6% to 3.2%)	0.85
PoCE	19.3% (150)	17.8% (141)	1.5% (-2.4% to 5.3%)	0.41
All-cause death	4.4% (34)	3.2% (25)	1.2% (-0.7% to 3.1%)	0.17
Cardiac death	1.7% (13)	1.1% (9)	0.5% (-0.2% to 1.7%)	0.17
Non-cardiac death	2.7% (21)	2.0% (16)	0.7% (-0.2% to 1.6%)	0.17
Any myocardial	7.3% (57)	7.7% (61)	-0.4% (-3.3% to 2.5%)	0.77
Target vessel MI	5.7% (44)	5.9% (47)	-0.3% (-2.6% to 2.0%)	0.81
Non-target vessel MI	1.8% (14)	2.3% (18)	-0.5% (-1.9% to 0.9%)	0.50



XXIX CONGRESO NACIONAL  
**CACI2019**

*Pilar*





XXIX CONGRESO NACIONAL  
**CACI2019**

*Pilar*



**COMING SOON 2020**





XXIX CONGRESO NACIONAL  
**CACI2019**

*Pilar*



 **MicroPort™**

**VitaFlow®**

Transcatheter Aortic Valve





XXIX CONGRESO NACIONAL  
**CACI2019**

*Pilar*



TODO EL EQUIPO DE  
MTG-GROUP LES DESEA...

**FELIZ**  
**2020**

